ストックスクリーナーアプリを入手
1.555
0.32%
0.005
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Promising Penny Stocks To Consider In June 2025 - simplywall.st
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha
Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news
Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times
Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan
Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors
Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus
Tiziana shares rise on presentation date for foralumab data - Seeking Alpha
Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news
Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times
Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan
Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World
TLSA Advances Alzheimer's Treatment with Innovative Nasal Spray - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - marketscreener.com
Tiziana Life Sciences Announces Interview Highlighting Intranasa - GuruFocus
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease | TLSA Stock News - GuruFocus
Tiziana Life Sciences Announces Breakthrough Advancement in Moderate Alzheimer’s Treatment with Intranasal Foralumab - Nasdaq
Breakthrough: First Alzheimer's Patient Shows Improvement with Revolutionary Nasal Antibody Treatment - Stock Titan
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace
Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive financial news
Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news
TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - The Manila Times
Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com
Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire
Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan
Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news
Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus
Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times
Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria
Tiziana reports promising Alzheimer’s treatment results - Investing.com
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace
Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors
Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive Investors
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors
TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus
Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha
Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com
Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE
Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news
Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news
Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha
Tiziana reports encouraging results for nasal MS drug in early study - Proactive Investors
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus
TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus
Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan
Tiziana shares surge 21% on promising multiple sclerosis data | NASDAQ:TLSA - Proactive Investors
Tiziana shares surge on encouraging results for nasal MS drug in early study - Proactive financial news
Geode Capital Management LLC Raises Stock Holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - Defense World
Tiziana Life Sciences Delays Annual Report Filing - TipRanks
1.35%
0.39%
大文字化:
|
ボリューム (24 時間):